Thiabendazole indications and usage: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
(2 intermediate revisions by the same user not shown)
Line 7: Line 7:
MINTEZOL is indicated for the treatment of:  
MINTEZOL is indicated for the treatment of:  


* [[Strongyloidiasis]] (threadworm)
* [[Strongyloidiasis]] ([[threadworm]])


* [[Cutaneous larva migrans]] (creeping eruption)
* [[Cutaneous larva migrans]] (creeping eruption)
Line 15: Line 15:
* [[Trichinosis]]: Relief of symptoms and [[fever]] and a reduction of [[eosinophilia]] have followed the use of MINTEZOL during the invasion stage of the disease.
* [[Trichinosis]]: Relief of symptoms and [[fever]] and a reduction of [[eosinophilia]] have followed the use of MINTEZOL during the invasion stage of the disease.


Thiabendazole is usually inappropriate as first line therapy for [[enterobiasis]] (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients.
Thiabendazole is usually inappropriate as first line therapy for [[enterobiasis]] ([[pinworm]]). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients.


MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable:  
MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable:  


* [[Uncinariasis]] (hookworm: [[Necator americanus]] and [[Ancylostoma duodenale]])
* [[Uncinariasis]] ([[hookworm]]: [[Necator americanus]] and [[Ancylostoma duodenale]])


* [[Trichuriasis]] (whipworm)
* [[Trichuriasis]] ([[whipworm]])


* [[Ascariasis]] (large roundworm)<ref>{{Cite web  | last =  | first =  | title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf | publisher =  | date =  | accessdate = }}</ref>
* [[Ascariasis]] (large [[roundworm]])<ref>{{Cite web  | last =  | first =  | title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 04:27, 12 January 2014

Thiabendazole
MINTEZOL® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indications and Usage

MINTEZOL is indicated for the treatment of:

  • Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.

Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients.

MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable:

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.